One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients

2011 ◽  
Vol 47 (10) ◽  
pp. 1521-1526 ◽  
Author(s):  
Atsunari Kawashima ◽  
Hitoshi Takayama ◽  
Yasuyuki Arai ◽  
Go Tanigawa ◽  
Mikio Nin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Dose Intensity ◽  
Progression Free Survival ◽  
Japanese Patients ◽  
Relative Dose Intensity ◽  
Advanced Renal Cell Carcinoma ◽  
Free Survival ◽  
Sorafenib Therapy

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

2011 ◽  
Vol 18 (0) ◽  
Author(s):  
Sebastien J. Hotte ◽  
G.A. Bjarnason ◽  
D.Y.C. Heng ◽  
M.A.S. Jewett ◽  
A. Kapoor ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Advanced Renal Cell Carcinoma ◽  
Free Survival ◽  
Clinical Trial Endpoint ◽  
Trial Endpoint

scholarly journals Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

2008 ◽  
Vol 7 (4) ◽  
pp. 496-501 ◽  
Author(s):  
Keith T. Flaherty ◽  
Mark A. Rosen ◽  
Daniel F. Heitjan ◽  
Maryann L. Gallagher ◽  
Brian Schwartz ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Pilot Study ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival ◽  
Dce Mri ◽  
Sorafenib Therapy

Everolimus treatment-associated interstitial lung disease (ILD) as a prognostic factor in Japanese patients with metastatic renal cell carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15531-e15531
Author(s):  
Fumiya Hongo ◽  
Masakatsu Oishi ◽  
Takashi Ueda ◽  
Yasunori Kimura ◽  
Terukazu Nakamura ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Interstitial Lung Disease ◽  
Prognostic Factor ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Japanese Patients ◽  
Free Survival

e15531 Background: Interstitial lung disease (ILD) is one of the adverse events during treatment with everolimus for metastatic renal cell carcinoma (mRCC). Japanese study of everolimus treatment-associated ILD as a prognostic factor is rare. Methods: We retrospectively assessed the incidence and outcome of ILD in mRCC patients treated with everolimus. Between April 2010 and August 2012, 25 cases were treated with everolimus after the failure of one or two TKIs in our institute. All adverse events were graded in accordance with NCI CTCAE, version 3.0. Results: A total of 25 patients received treatment with everolimus and included 18 male and 7 female patients ranging in age from 21 to 84 years (median 62). According to MSKCC risk criteria, 6 cases were at favorable risk, 16 cases were at intermediate risk, and 3 cases were at poor risk. The median treatment term was 4 months (range 2-17 months). SD was reported in 19 cases and PD in 6 cases. Progression free survival was 3.5 months and overall survival was 12 months. ILD was found in 7 cases (28%). One was G1, five were G2, and one was G3. Corticosteroid therapy was initiated in 3 cases. In 5 of 7 ILD cases, everolimus was re-challenged. In our series, patients with ILD showed significantly better progression free survival than those without ILD (PFS was 8 months vs 3 months. Log-rank, P<0.001). There were no significant differences between the two groups in overall survival (12 months in patients with ILD vs 10 months in patients without ILD. Log-rank, NS). Conclusions: Everolimus appears to have been effective and well-tolerated in our institute. Re-challenge with everolimus was feasible after improving everolimus-induced ILD in cases of grade 1-2. To confirm these findings, the efficacy and AE profile of everolimus in Japanese patients should be investigated.

Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

2012 ◽  
Vol 15 (6) ◽  
pp. 1139-1148 ◽  
Author(s):  
Michael K. Wong ◽  
Ateesha F. Mohamed ◽  
A. Brett Hauber ◽  
Jui-Chen Yang ◽  
Zhimei Liu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Advanced Renal Cell Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Free Survival

scholarly journals Metastatic renal cell carcinoma kidney in children 10 years old – possibility of targeted therapy

2018 ◽  
Vol 13 (4) ◽  
pp. 126-132
Author(s):  
A. Yu. Pavlov ◽  
Z. R. Sabirzyanova ◽  
O. G. Zheludkova ◽  
A. V. Mikhalchenko
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clinical Observation ◽  
Radical Surgery ◽  
Treatment Protocol ◽  
Progression Free Survival ◽  
Free Survival ◽  
Sorafenib Therapy

Renal cell carcinoma (RCC) is rare in children, its metastatic form is even rarer. At present there is no treatment protocol for children with RCC. This clinical observation presented the patient 10 year old with RCC metastases to the lungs. After radical surgery, after targeted sorafenib therapy the patient has a positive dynamics. At present his progression-free survival is 30 months.

scholarly journals Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib

Oncology ◽  
2015 ◽  
Vol 89 (4) ◽  
pp. 235-241 ◽  
Author(s):  
Michael W. Kattan ◽  
Cora N. Sternberg ◽  
Faisal Mehmud ◽  
Kamal Bhatt ◽  
Lauren McCann ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Advanced Renal Cell Carcinoma ◽  
Free Survival ◽  
Development And Validation
Sign in / Sign up

Export Citation Format

Share Document